Results per Page:
Location, location, location: where is key for CAR T-cell therapy
From the Walter lab, Translational Science and Therapeutics Division
TIME and space predict response to CAR T-cell therapy in lymphoma
From the Hirayama and Turtle labs, Clinical Research Division
If at first you don’t succeed: Testing outcomes of second CAR T-cell infusions
From the Turtle group and collaborators, Clinical Research Division
Antiviral immunity survives CD19-directed therapy
From the Hill and Turtle laboratories, Vaccine and Infections Disease Division and Clinical Research Division
Try, try again: Can a 2nd dose of CAR T cells succeed when the first fails?
First-of-its-kind study offers early indication of factors linked to increased odds of success for patients out of options
Dr. Cameron Turtle receives Anderson Family Endowed Chair for Immunotherapy
Gift will ‘help new ideas move rapidly toward the patients who need them’
Cytokines may give CD19 CAR-T cells a boost
From the Turtle Laboratory, Clinical Research Division
Colette Chaney named ‘2018 Nurse of the Year for Research Advancement’
March of Dimes Washington honors the longtime immunotherapy clinical research nurse
3 new projects map out immune responses to cancers
Scientists aim to gather knowledge that improves future immunotherapies
Fred Hutch at ASCO
Immunotherapy advances, insights into health economics and leadership awards dominate oncology gathering
3 big new leukemia research projects advance cutting-edge cell therapies, stem cell transplant
$20M renewal of 4-decade-long federal grant to Hutch scientists
Learning more from T-cell therapy trials
Fred Hutch Immunotherapy Integrated Research Center awards grants to Drs. Brian Till, Cameron Turtle
How new drugs become available to more patients
Filling in the unknowns on the balance between risk and benefit
10 highlights of Fred Hutch science in 2017
A look back at notable discoveries in cancer immunotherapy, HIV prevention and more
New insights into CAR T-cell therapy's potential side effects
Detailed study of cytokine release syndrome and neurologic toxicities could help make emerging cancer immunotherapies safer
First systematic study of infections after CAR T-cell therapy
“Benchmark” research could help reduce complications of emerging immunotherapy
Science without borders
At Fred Hutch and other U.S. research centers, a global village works to cure cancer and other diseases
Promising results in trial of engineered T cells in high-risk leukemia
High response rates to experimental immunotherapy in patients with treatment-resistant chronic lymphocytic leukemia
‘A place where miracles happen’: Opening of Bezos Family Immunotherapy Clinic highlights patient-focused science
Research symposium and ribbon cutting celebrates first-of-its-kind facility for experimental immunotherapies
Patients with advanced lymphoma in remission after T-cell therapy
New study: 7 of 11 trial participants who got two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission